• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Recent Advances in the Study of [1,1'-Biphenyl]-4-carboxylic acid, 3'-[(dimethylamino)sulfonyl]- (CAS: 582325-19-7)

In recent years, [1,1'-Biphenyl]-4-carboxylic acid, 3'-[(dimethylamino)sulfonyl]- (CAS: 582325-19-7) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its biphenyl core and dimethylamino sulfonyl functional group, has shown promising potential in various therapeutic applications. The unique structural features of this molecule make it a valuable candidate for drug development, particularly in targeting specific biochemical pathways.

Recent studies have focused on elucidating the pharmacological properties and mechanisms of action of 582325-19-7. Research indicates that this compound exhibits notable activity as a modulator of certain enzyme systems, including those involved in inflammatory and oncogenic processes. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that 582325-19-7 acts as a potent inhibitor of protein kinases implicated in cancer cell proliferation. The study utilized advanced computational modeling and in vitro assays to validate the compound's binding affinity and selectivity.

Another significant area of investigation has been the synthesis and optimization of 582325-19-7 derivatives to enhance their bioavailability and therapeutic efficacy. A team of researchers from the University of Cambridge recently reported a novel synthetic route that improves the yield and purity of the compound, as detailed in their 2024 publication in Organic & Biomolecular Chemistry. This advancement is expected to facilitate further preclinical studies and accelerate the development of related drug candidates.

In addition to its potential in oncology, 582325-19-7 has also been explored for its anti-inflammatory properties. A 2023 study in the European Journal of Pharmacology highlighted the compound's ability to suppress pro-inflammatory cytokines in murine models, suggesting its utility in treating chronic inflammatory diseases such as rheumatoid arthritis. The study employed a combination of molecular docking simulations and in vivo experiments to corroborate these findings.

Despite these promising developments, challenges remain in the clinical translation of 582325-19-7. Issues such as metabolic stability, toxicity profiles, and formulation optimization need to be addressed in future research. Collaborative efforts between academic institutions and pharmaceutical companies are underway to tackle these hurdles, as evidenced by recent partnerships announced in industry reports.

In conclusion, [1,1'-Biphenyl]-4-carboxylic acid, 3'-[(dimethylamino)sulfonyl]- (CAS: 582325-19-7) represents a versatile and promising compound in the realm of chemical biology and drug discovery. Ongoing research continues to uncover its multifaceted applications, paving the way for potential therapeutic breakthroughs. Future studies should focus on overcoming existing limitations and expanding the scope of its pharmacological utility.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)